Search Results

Press Releases

PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients

January 16, 2025

·

3 min read

Biotech Beach

PreludeDx Presents New Data Highlighting Ability of DCISionRT® to Predict Benefit of Radiation Therapy in DCIS Patients, Independent of Endocrine Therapy (ET)

Prelude Corporation (PreludeDx ® ), a leader in precision diagnostics for early-stage breast cancer, today announced that it will share data demonstrating the power of its DCISionRT ® test to better predict radiation therapy (RT) benefit in comparison to clinicopathologic risk factors for women with ductal carcinoma in situ.

May 30, 2024

·

3 min read

Biotech Beach

PreludeDx™ Presents New Data Demonstrating Utility of DCISionRT® to De-escalate Radiation Therapy for Women with DCIS

Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, presented data on the use of DCISionRT® to identify a subset of patients with high-risk clinicopathology who had a low 10-year risk of in-breast recurrence (IBR) and no significant benefit from radiation therapy (RT).

April 11, 2024

·

4 min read

Biotech Beach

PreludeDx Welcomes Dr. Pat Whitworth as Chief Medical Officer to Drive Expansion of Precision Diagnostics

Prelude Corporation, a leader in precision diagnostics for early-stage breast cancer, announced the appointment of Dr. Pat Whitworth as its new Chief Medical Officer.

May 2, 2024

·

4 min read

Business

PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business Development

Prelude Corporation today announced the appointment of Chris Emery to the newly created position of VP of Strategic Marketing and Business Development.

February 8, 2024

·

4 min read

BioCapital

PreludeDx™ to Present New Data in DCIS and Early-Stage Invasive Breast Cancer at the American Society of Breast Surgeons Annual Meeting

Prelude Corporation announced that data will be highlighted in a Quickshot Scientific Session and poster presentation at the 25th American Society of Breast Surgeons Annual Meeting, to be held on April 10 - 14, 2024 at the Orlando World Center Marriott.

April 3, 2024

·

3 min read

Biotech Beach

PreludeDx™ Announces New Contract with MediNcrease Health Plans for its Novel DCIS Test, DCISionRT®

Prelude Corporation announced it has entered into a managed care provider agreement with MediNcrease Health Plans, a national provider network in the US, to make accessible the PreludeDx’s DCISionRT® test to its clients and payers.

February 28, 2023

·

4 min read

Biotech Beach

PreludeDx™ Announces Novel Test for Predicting Radiation Therapy Benefit and Recurrence Risk in Early-Stage Invasive Breast Cancer Patients

Prelude Corporation has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast.

March 14, 2024

·

5 min read

Biotech Beach

PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

Prelude Corporation today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.

February 22, 2024

·

4 min read

Biotech Beach

DCISionRT® by PreludeDx™ Receives Advanced Diagnostic Laboratory Test (ADLT) Status Approval from the Centers for Medicare & Medicaid Services

Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status effective April 1, 2023, for the DCISionRT® test.

March 28, 2023

·

3 min read